Novel SARS-CoV-2 spike variant identified in Washington, D.C.

1	Novel	SARS-CoV-2 spike variant identified through viral genome sequencing of the
2	pediat	ric Washington D.C. COVID-19 outbreak.
3		
4	Jonath	an LoTempio <sup>1,2</sup> , Erik Billings <sup>3</sup> , Kyah Draper <sup>3</sup> , Christal Ralph <sup>3</sup> , Mahdi Moshgriz <sup>3</sup> , Nhat
5	Duong	<sup>3</sup> , Jennifer Dien Bard <sup>4,5</sup> , Xiaowu Gai <sup>4,5</sup> , David Wessel <sup>6,7,8</sup> , Roberta L. DeBiasi <sup>8,10,11</sup> ,
6	Josepl	n M. Campos <sup>3,8,9,10</sup> , Eric Vilain <sup>1,2</sup> , Meghan Delaney <sup>3,8,10</sup> , Drew G. Michael <sup>1,2,3,8,#</sup>
7		
8	1.	Children's National Hospital, Center for Genetic Medicine Research
9	2.	George Washington University School of Medicine and Health Sciences, Department of
10		Genomics and Precision Medicine
11	3.	Children's National Hospital Division of Pathology and Laboratory Medicine Department
12	4.	Children's Hospital of Los Angeles, Department of Pathology and Laboratory Medicine
13	5.	Keck School of Medicine, University of Southern California
14	6.	Children's National Hospital, Division of Cardiology
15	7.	Children's National Hospital, Division of Critical Care Medicine
16	8.	George Washington University School of Medicine and Health Sciences, Department of
17		Pediatrics
18	9.	George Washington University School of Medicine and Health Sciences, Department of
19		Microbiology, Immunology and Tropical Medicine
20	10	. George Washington University School of Medicine and Health Sciences, Department of
21		Pathology
22	11	. Children's National Hospital, Division of Pediatric Infectious Diseases
23	# Addr	ress correspondence to Drew G. Michael <u>dgmichael@childrensnational.org</u>
24		
25	Runnir	ng head: Novel SARS-CoV-2 spike variant identified in Washington, D.C.

Abstract word count: 197 | Importance word count: 148 | Main paper word count: 4230

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

2

# 27 ABSTRACT

28 The SARS-CoV-2 virus has emerged as a global pandemic, severely impacting everyday life. 29 Significant resources have been dedicated towards profiling the viral genome in the adult 30 population. We present an analysis of viral genomes acquired from pediatric patients presenting to Children's National Hospital in Washington D.C, including 24 with primary SARS CoV2 31 32 infection and 3 with Multisystem Inflammatory Syndrome in Children (MIS-C) undergoing 33 treatment at our facility. Viral genome analysis using next generation sequencing indicated that 34 approximately 81% of the analyzed strains were of the GH clade, 7% of the cases belonged to 35 the GR clade, and 12% of the cases belonged to S, V, or G clades. One sample, acquired from 36 a neonatal patient, presented with the highest viral RNA load of all patients evaluated at our 37 center. Viral sequencing of this sample identified a SARS-CoV-2 spike variant, S:N679S. 38 Analysis of data deposited in the GISAID global database of viral sequences shows the 39 S:N679S variant is present in eight other sequenced samples within the US mid-Atlantic region. 40 The similarity of the regional sequences suggests transmission and persistence of the SARS-41 CoV-2 variant within the Capitol region, raising the importance of increasing the frequency of 42 SARS-CoV-2 genomic surveillance. 43 44 **IMPORTANCE** A variant in the SARS-CoV-2 spike protein was identified in a febrile neonate

45 who was hospitalized with COVID-19. This patient exhibited the highest viral RNA load of any 46 COVID-19 patient tested at our center. Viral sequencing identified a spike protein variant, 47 S:N679S, which is proximal to the cleavage site at residue 681. The SARS-CoV-2 surface spike 48 is a protein trimer (three subunits) which serves as the key target for antibody therapies and 49 vaccine development. Study of viral sequences from the GISAID database revealed eight 50 related sequences from the US mid-Atlantic region. The identification of this variant in a very 51 young patient, its critical location in the spike polyprotein, and the evidence that it has been 52 detected in other patients in our region underscores the need for increased viral sequencing to

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

3

monitor variant prevalence and emergence, which may have a direct impact on recommended
public health measures and vaccination strategies.

55

#### 56 **INTRODUCTION**

SARS-CoV-2, a positive-sense single-stranded RNA virus, is the causative agent of the ongoing COVID-19 pandemic (1–3). Reports in early 2020 suggested that children were spared the harshest manifestations of disease, with the majority of patients reported as asymptomatic (4). The first wave of outbreaks across Europe and the Americas demonstrated that this was not the case (5, 6), and in addition to the classical array of COVID-19 symptomatology, children were shown to be susceptible to a novel disease presentation, Multi-system Inflammatory Syndrome

63 in Children (MIS-C) (7, 8) .

64

65 Children's National Hospital (CNH) in Washington, D.C., has evaluated and treated large 66 numbers of pediatric and young adult patients with both primary SARS-CoV2 infection as well 67 as MIS-C. The volume of patients seeking care has mirrored trends seen on the US East 68 Coast, with an early spring 2020 peak, summer plateau, and an ongoing wave of infections 69 which began in late November. As of January 12th, 2021, at least 821 Washingtonians have 70 died of COVID-19, representing over 0.1% of the District of Columbia (D.C.) population (9), 71 although none of these deaths have occurred in children at CNH, despite hundreds requiring 72 hospitalization. Accordingly, our institution has allocated significant resources to understand the 73 multi-factorial nature of SARS-CoV-2 primary infection and MIS-C.

74

The diagnosis of suspected COVID-19 patients at CNH, which includes D.C., Maryland,
Virginia, West Virginia, and Delaware in its hospital catchment area, is routinely performed
using semi-quantitative RT-PCR commercial platforms with EUA approved tests designed to
assess multiple loci within the SARS-CoV-2 genome. When a test returns as positive, that

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

4

79	patient enters treatment following a protocol designed to optimize care and resources. For
80	selected samples, virus samples underwent viral sequencing to characterize the nature of the
81	viral strains in our region.
82	
83	Analysis of one viral isolate from a neonatal patient with a high viral RNA load resulted in the
84	identification of a novel spike protein variant representing the earliest known sample of an
85	emergent SARS-CoV-2 lineage in the US mid-Atlantic region. As the vaccine rollout for SARS-
86	CoV-2 continues, the identification of this variant in the viral spike protein highlights the need for
87	consistent, comprehensive molecular monitoring, transparency in reporting, and rapid response
88	at all levels of healthcare and pandemic response systems.
89	
90	RESULTS
91	
92	Genomic profiling of pediatric COVID-19 SARS-CoV-2 virus in the Washington D.C. area
93	identifies the GH clade as the predominant local viral clade. Seventy-six samples from
94	COVID-19 patients presenting at CNH were selected for viral sequencing. Of these, twenty-
95	seven samples met genetic sequencing coverage criteria for further analysis (>1,000 mean
96	coverage), allowing for consensus sequences to be built and used for phylogenetic and variant
97	analysis.
98	
99	Viral sequences were analyzed via multiple sequence alignment (MSA) using ClustalW
100	alongside representative samples from each viral clade as annotated in the Global Initiative on
101	Sharing All Influenza Data (GISAID) repository and summarized in <u>S1</u> . The phylogenetic
102	relationship between our viral samples Fig. 1A, allows for comparison to samples deposited
103	from other laboratories in the D.C. area Fig. 1B. These data indicate that the pediatric COVID-

104 19 outbreak within the D.C. area followed trends observed in the adult population, as

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

5

established by the clades of viruses deposited in the Global Initiative on Sharing All Influenza
Data (GISAID) database and annotated for our geographic locale (*Fig. 1B*). This finding
supports the hypothesis that the viral strains propagating in adults are similar to those in
children.

109

110 The D.C. outbreak mirrored the New York State (NYS) outbreak in terms of early predominance 111 of sequences assigned to the GH clade. Genetic differences in outbreaks over time can be seen 112 when examining key US West Coast outbreaks, as well as the early Chinese outbreak, where 113 different clades of the virus reached equilibrium as the pandemic progressed (Fig. 1B). Analysis 114 of the distribution of deposited viral sequences over time allows for the coarse analysis of 115 predominant strains in each area. In the D.C. area, along with NYS, Washington State, and 116 California. The ratio of clades present in each location changes with an increase in deposited 117 viral sequences, demonstrating the evolving and dynamic nature of the SARS-CoV-2 variant 118 profile across the pandemic.

119

120 To assess the possible geographic origin of viral strains propagating locally, we utilized the 121 Phylogenetic Assignment of Named Global Outbreak LINeages, or PANGOLIN tool. PANGOLIN 122 leverages data deposited at GISAID to assign lineages and find near global genetic neighbors 123 based on their internal variant-based lineage assignment, which allows for sequence level 124 analysis of global relationships. The countries which had the highest number of sequence 125 submissions with the same lineages as our 27 samples were the US, United Kingdom (UK), and 126 France, with minor relationships to sequences deposited from Portugal, Australia, Israel, and 127 New Zealand (Fig. 2).

128

The results point toward a European origin for the virus propagating in the US Capitol region
 pediatric population. The observation of the US and UK as major locations of genetic similarity

#### Novel SARS-CoV-2 spike variant identified in Washington, D.C.

6

131	is consistent with domestic population flux across US state borders, which remain porous, as
132	well as international population flux, which was restricted with China on January 31, 2020, but
133	unrestricted with Europe generally until March 11, 2020 (10, 11). Considering this, the
134	incomplete nature of early travel restrictions does not appear to have had a protective effect on
135	the US population. The UK is an outsized-GISAID contributor, responsible for sharing over
136	104,000 of the 263,000 high-quality, complete genomes in GISAID as of January 12,
137	contributing to its weight in comparison to the samples sequenced in D.C. The third highest
138	genetic contributor, France, was likely an early contributor to our outbreak in the D.C. area as
139	determined by the presence of variants specific to the GH lineage samples found both in the
140	Washington Metro region and first identified in France in February 2020 (DeBiasi et al,
141	unpublished data under review). One limitation of the use of the PANGOLIN tool is that, since it
142	is tied to the ever-expanding GISAID resource, relationships over time may change based on
143	newly-deposited viral sequences.
144	
145	Viral variant profile of three pediatric MIS-C patients highlights the complexity of COVID-
146	19 genotype-phenotype associations. To attempt correlation of SARS-CoV-2 variants with
147	phenotypic outcomes, we identified consensus variants within the viral genome and overlaid the

distribution of viral genetic variants with patient MIS-C clinical status. These analyses identified
multiple variants present within each viral sample. Of note, 92% (25/27) of the viral genomes
within the sampled cases contained the S:D614G spike variant associated with increased viral
transmissibility (12).

152

Interestingly, five patients were identified with identical viral variant profiles. Four of these
patients presented with primary COVID-19 disease and one presented with MIS-C. These
samples are distinguished from other sequences assigned to the GH clade by the presence of
variants in both the nucleoprotein (N:S193I) and non-structural protein 2 (NSP2:T371I), (*Fig. 3*).

In the GISAID database, 1198 sequences have N:S193I, while 277 have NSP2:T371I - only

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

157

158	seven have both (GISAID accessions: EPI_ISL_516718, EPI_ISL_683413, EPI_ISL_745300,
159	EPI_ISL_676627, EPI_ISL_683422, EPI_ISL_710051, EPI_ISL_683418). Six of those seven
160	were generated from samples originating in Texas in late July, while the final sequence was
161	generated from a sample originating in Virginia collected on April 30, 2020.
162	
163	All patients presenting with MIS-C shared two GH clade-specific variants (NSP2:T85I and
164	ORF3a:Q57H) with other samples from patients who presented with primary COVID-19. One,
165	which was identical to other previously-discussed samples, had nucleocapsid variants N:S193I
166	and NSP2:T371I. The second had the additional variant NSP1:L16I, while the third had
167	NSP3:T424I and NSP8:A45V.
168	
169	The observation of five identical viral genomic profiles with different disease outcomes, and two
170	clinically similar MIS-C cases with different viral genotypes highlights the difficulties inherent in
171	forming viral genotype-human phenotype correlations in this disease ( <i>Fig. 3</i> ). This observation
172	points toward the importance of additional variables, such as initial viral dosage, environmental
173	factors, and host genetic predispositions as key elements of COVID-19 progression and
174	possibly underlying MIS-C presentation.
175	
176	High viral RNA load on presentation in neonatal patient leads to identification of novel
177	spike protein S:N679S variant. In early September 2020, a febrile neonatal patient was
178	hospitalized at CNH with COVID-19 symptoms. SARS-CoV-2 RT-PCR testing detected a high
179	diagnostic viral load as measured by the polymerase chain reaction (PCR) cycle threshold (Ct)
180	of 6.45 using an assay which targets ORF (Ct 6.4) and spike (Ct 6.5) (Simplexa COVID-19
181	Direct, Diasorin, CA, USA). In comparison, we observed a median Ct of 22.1 for both genes
182	during 499 previous positive tests. The observed Ct for this patient represented an approximate

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

8

183	51,418-fold increase in viral load compared to the median presenting viral load in previously
184	seen patients. Supplemental testing of this patient's sample on a different platform yielded a Ct
185	of 6.5 (Allplex™ 2019-nCoV Assay, Seegene, S Korea) confirming the extremely high viral load.
186	As this patient represented an outlier in viral load, we selected this sample for NGS profiling of
187	the SARS-CoV-2 genome.
188	
189	Short read sequencing analysis of the SARS-CoV-2 genome identified a novel variant which
190	resulted in the nonsynonymous amino acid substitution S:N679S, which is responsible for viral
191	entry. The presence of >9,000 individual reads was strong support for a spike protein variant,
192	rather than a sequencing error or artifact of PCR (Fig. 4B). In order to confirm with an
193	orthogonal sequencing technology, the sample was sent for confirmation of the variant by
194	Sanger sequencing, which confirmed the presence of the S:N679S variant (Fig. 4C). The
195	Sanger data analysis also confirmed the presence of the S:D614G variant in the viral genome,
196	which is present in the majority of global samples due in part to its hypothesized greater
197	infective potential (12). This is significant, as association of the S:N679S with S:D614G may
198	contribute to the persistence of the S:N679S variant.
199	
200	To assess where the S:N679S variant is present in the community, we queried the GISAID
201	database. At the time of the initial query, the GISAID database contained six high-quality
202	complete genomes containing the S:N679S variant. All six of these genomes were deposited by
203	labs in Maryland and Virginia. In mid-December, 2020 re-query identified an additional four
204	samples from Australia and Japan, with a third re-query revealing a sequence from Brazil.
205	Finally, a fourth query on January 12, 2021 revealed two more high-quality sequences from
206	Delaware. Phylogenetic analysis (Fig. 5A) showed that this novel spike variant had emerged in
207	two distinct viral clades which are geographically and genetically independent of each other.

208 Variant profiles and lineage assignments suggest the singleton samples from Brazil and Japan,

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

9

209 and the samples from Australia, while all in clade GR, are genetically distinct in lineages 210 B.1.1.33, B.1.1.284, and B.1.1.162, respectively. Conversely, all samples collected in the US 211 were assigned to the lineage B.1.189 by PANGOLIN, further supporting their similarity within the 212 large G clade. 213 214 To probe the similarity between the reported samples of US origin, we constructed a maximum-215 likelihood (ML) phylogeny with international samples for context (Fig. 5A). The tree topology 216 among US mid-Atlantic regional samples is consistent with time-of-sampling metadata, which is 217 available for all US samples. The patient treated at CNH, who exists in a branch distinct from 218 the other six samples from the D.C. area, was sampled on 17 days before the next earliest 219 sample on September 23rd. Both samples from Maryland collected on October 20, as well as 220 one from October 13 are genetically identical with branch length zero. It is remarkable that 221 samples collected on the 20th and 21st of October in Delaware share a common ancestor 222 predating the samples found locally (including our sample from September 7, 2020). This 223 suggests both the persistence of the variant, and earlier emergence than was previously 224 appreciated with samples from the District of Columbia, Maryland, and Virginia. 225 226 Spike protein residue 679 is proximal to the S1/S2 cleavage site and may impact function. 227 We queried GISAID for all amino acid substitutions at spike polyprotein position 679, the results 228 of which are presented in S2 a. The most common variants observed so far include substitution 229 with lysine or deletion, both of which represent 703 of 731 variants described in all human 230 sequences in GISAID. Substitution with serine, the variant observed at CNH, represented 16 231 human sequences as of January 12, 2021. Five substitutions to histidine, two to isoleucine, two 232 to tyrosine, and one to threonine were also observed. There are over 370,000 sequences 233 containing the wild-type asparagine. 234

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

10

235 The relatively high number of lysine variants can be partially attributed to codon wobble - both 236 have tRNA three letter codes AAX, with asparagine coded by AAU and AAC, while lysine is 237 coded by AAA and AAG. The serine, threonine, and tyrosine require transition or transversion at 238 the second position of the codon, while transversion of the first codon position is required to 239 result in histidine. A multifasta (S2\_b) with each of these amino acid substitutions, and a 240 deletion of the residue at 679 was constructed and analyzed with the ProP tool for predicting 241 cleavage sites (13). With the exception of the S:N679Y variant, each substitution scored higher 242 than the wild type threshold of 0.62. Higher ProP scores indicate a higher likelihood the site will 243 function as a site for cleavage. This suggests our observed S:N679S substitution at this residue 244 does not preclude the variant protein from activation. A robust and rapid pipeline for functional 245 classification of SARS-CoV-2 variants will be an important public health tool as the global 246 community continues to navigate the COVID-19 pandemic.

247

248 In 2011, it was shown that SARS-CoV spike protein is cleaved and activated by human airway 249 trypsin-like protease (HAT)(14). Furthermore, it has been suggested that the insertion of the 250 RRAR amino acid sequence at the S1/S2 cleavage site in SARS-CoV-2, relative to SARS-CoV, 251 represents a gain of function as a target of human peptidase furin, which is known to cleave 252 basic amino acids at the motif R–X–[R/K]–R. This motif is indeed observed between S1 and S2 253 spike subunits in SARS-CoV-2. In silico and benchtop experimental evidence has been 254 presented for SARS-CoV-2 variants with and without this motif showing SARS-CoV-2 variants 255 lacking the RRAR motif are unable to fuse with HEK293 cells in the absence of trypsin or HAT, 256 while the wild type SARS-CoV-2 spike can undergo cellular fusion without HAT or trypsin (15). 257

This is strong evidence for a cell fusion gain of function through the RRAR protein motif – but
not for an increase in virulence or infectivity. Indeed, SARS-CoV-2 variants where the furin
cleavage site has been deleted show increased infectivity (16, 17). Whether preservation of the

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

11

furin cleavage site and its gain of function for cell fusion relative to SARS-CoV is outweighed by the increase in infectivity in its absence (as in SARS-CoV-2) should be functionally assessed in cell and animal experiments.

264

265 Analysis of global SARS-CoV-2 data provides evidence for mid-Atlantic circulation of the 266 spike variant S:N679S. As of January 12, 2021, there are 161 sequences in GISAID which are 267 annotated as B.1.189 (including low quality sequences) which represent the nearest genetic 268 neighbors of our sample of interest. Of these sequences, 149 are from the US, nine are from 269 Mexico, two are from Canada, and one is from Japan. The earliest available sequences were 270 from samples collected in March in California and Mexico City. Two samples from Manitoba, 271 Canada, were collected in May, and the single sample from Japan was collected in July. 272 Examination of the temporal and geographic distribution of this lineage further suggests 273 circulation in North America, from coast to coast, and across the Mexican-American, and 274 Canadian-American borders (Fig. 5 B). Variant analysis with NextClade (18) shows only two 275 silent mutations present inside and outside the D.C. area - A20268G and C4582T - suggesting 276 the possibility of many missing representatives of the lineage. 277 278 The S:N679S-containing sample detected at CNH has silent mutation C2710T, which is absent 279 in all other local samples. All D.C. area samples contain two missense mutations, 280 ORF1a:A2994V and ORF1a:P3359S, as well as silent mutation T11408C. The difference 281 between these samples suggests there is likely an earlier case which has the additional variants 282 common to all seven samples including missense mutations ORF1a:K564Q, ORF1a:P2018L, 283 ORF1a:S3885F, ORF1b:H2583Y, and ORF3a:S177I, as well as silent mutations C4276T, 284 T6160C, C16293T, C16887T, C26222T. This predicted most recent common ancestor, likely 285 appeared in summer 2020. Additional sequencing of archived samples will be required to 286 assess this hypothesis.

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

12

288	When considering that there are two high-quality sequences in the database are from samples
289	acquired in Delaware, the timeline can be revised to include longer circulation and wider spread.
290	Those samples contain the coding variants ORF1a:S3885F, ORF1b:P314L, ORF1b:H2583Y,
291	ORF3a:S177I, S:D614G, S:N679S, which are common to the samples from the D.C. area. One
292	sample, EPI_ISL_803105 collected on October 20, also has ORF1a:K564Q which is common to
293	the D.C. region samples, while the other, EPI_ISL_803106 collected one day later, does not
294	have that variant which possibly represents a loss of the variant through back mutation to the
295	reference nucleotide, A, at position 1955. These sequences also contain further coding variants
296	ORF10:Q29* and ORF1a:C1114F, but lack all other ORF1a variants.
297	
298	Taken together, these data support the hypothesis wherein a SARS-CoV-2 virus containing the
299	variant S:N679S is circulating within the US mid-Atlantic region. Based on these analyses, the
300	ancestral state is hypothesized to include the following variants: ORF1a:K564Q,
301	ORF1a:S3885F, ORF1b:P314L, ORF1b:H2583Y, ORF3a:S177I, S:D614G, S:N679S. All other
302	variants are lineage specific. All variant profiles of these sequences can be found in S1.
303	
304	Low sequencing rates in the US hinder surveillance of emerging viral variation. As of
305	January 12, the US has passed 25 million reported cases and 433,000 reported deaths; the
306	range of excess deaths in the US reported by the CDC and attributed to COVID-19 was given a
307	lower bound of 346,750 and an upper bound of 469,831 (19). Concurrently, approximately
308	
000	71,000 sequences deposited to GISAID are from the US, representing ~0.3% of confirmed
309	71,000 sequences deposited to GISAID are from the US, representing ~0.3% of confirmed cases. We leverage data from Australia (59.6% of confirmed cases, or 17,081/28,650 cases

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

13

sequences deposited from 3.16 million cases (~4.99%). All data are based on GISAID

submissions and the Johns Hopkins' interactive dashboard (20).

314

315 Our analysis of the S:N679S containing viral genome from sample CNH-B-40 began in early

316 December; other local high-quality sequences with the variant had been deposited just weeks

317 prior. In the intervening four weeks, the sequences from Australia, Japan, and Brazil were

deposited, along with another low-quality sequence from Delaware in the US. This brings the

total number of high-quality sequences from human samples in GISAID with S:N679S to twelve,

including CNH-B-40 which is yet to be assigned a GISAID accession number.

321

322 The highly-related samples with S:N679S were all collected over a large, interconnected 4-

323 state/district geographic area in a relatively short 7-week timeframe with no established person-

324 to-person transmission network. Given the high likelihood of community circulation of this

325 variant of SARS-CoV-2, it is possible that additional cases of this variant strain are present in

326 the mid-Atlantic region but have yet to be detected due to low rates of viral sequencing and

deposition to GISAID.

328

329 As of January 12, Delaware has approximately 67,000 confirmed cases and 345 sequences 330 deposited (0.5%), Maryland has 315,000 confirmed cases and 802 sequences deposited 331 (0.25%). D.C. has 33,000 confirmed cases and 130 sequences deposited (plus our 27) (0.4%, 332 0.47% combined), and Virginia has 413,000 confirmed cases and 1,685 sequences deposited 333 (0.4%). Taken together, in states from this region, there are at least 828,000 cases, but only 334 2,962 sequences. This represents a sequencing rate of 0.36%, just over the national average of 335 0.3%, but considerably lower than the 4.99% of samples sequenced in the UK, where a critical 336 new variant was first identified (21, 22).

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

14

## 338 DISCUSSION

339 A key goal of precision medicine is to target care to those who need it most. An ideal COVID-19 340 diagnostic and triage algorithm would integrate features such as viral genomic profile, host 341 innate errors in immunity and viral load over the course of infection to inform care. Toward this 342 end, we established systems to profile the SARS-CoV-2 genome and link viral genotype to 343 pediatric disease outcomes. This report contains the initial analysis of twenty-seven patients 344 and highlights the complexity of generating effective viral genotype-human phenotype 345 correlations. Given the complex, multifactorial nature of COVID-19, larger pediatric studies 346 which link to phenotypic outcomes will be required. 347

348 We note the parallel between the emergence of antibiotic resistance traits in bacteria (23, 24) 349 and viral evolution. Physical and social distancing measures have presented a transmission and 350 genetic bottleneck to SARS-CoV-2, with data supporting a different mix of virus clades in each 351 successive wave. The wide-scale development and deployment of vaccines for SARS-CoV-2 352 will present further bottlenecks to the virus. These measures, while demonstrably effective, have 353 the potential to drive the evolution of strains capable of bypassing defenses. The emergence of 354 the D614G variant and the increased infectivity of the UK variant strain B.1.1.7 / UK VUI 355 202012/01 strain highlight the potential for stochastic genomic variants to generate vaccine 356 escaping viral strains and to exhibit altered SARS-CoV-2 fitness (12, 22).

357

At present, there is high-quality, genomic evidence which supports the biological tolerance or persistence of the S:N679S variant in at least two distinct clades. This includes the variant S:N679S in the GR clade found in Brazil, Japan, and Australia, and the variant found in G clade in September and October of 2020 in the US mid-Atlantic region. While the sequences from Brazil, Japan, and Australia have been assigned the GR clade, they do not belong to the same PANGOLIN lineage due to variation in their genomes, which we can see recapitulated in the

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

15

tree topology of Fig. 5a. This is strong evidence for four different evolutionary events which are
 tolerated in GR and G SARS-CoV-2 clades.

366

367 The UK presents a strong case for widespread use of high throughput sequencing technologies 368 and rapid data sharing so that discoveries like these are more rapidly made, confirmed, and 369 acted upon. Under current funding levels, the US CDC plans to fund the sequencing and 370 release of at least 6,000 viruses per week as reported on January 4, 2021 (25, 26). This 371 represents approximately 0.4% of daily cases based on current daily caseloads in excess of 372 200,000. This is still well below the UK's level of sequencing (4.99%), but is a commendable 373 step in the right direction, assuming that samples that are sequenced will be representative of 374 the population, allowing for surveillance. Inclusion of data on disease severity, patient age and 375 ethnicity, co-morbidities, and other relevant contextual data will help researchers ascertain the 376 generalizability of sequences in hand, or adjust for confounding factors as needed. Further 377 funds should be allocated to promote a collaborative effort to sequence biobanked samples in 378 an effort to understand viral evolution and transmission paths.

379

380 Our analyses identified the S:N679S variant within a neonatal patient with a high observed viral 381 load at presentation. This single case observation currently represents insufficient evidence to 382 propose a causal relationship between the S:N679S variant and increased viral loads or 383 presentation at a very young age. Analysis of the GISAID data for pediatric enrichment was not 384 possible due to the lack of patient metadata for records with this variant. The observation that 385 this variant strain of SARS-CoV-2 is currently undergoing community transmission in the US 386 mid-Atlantic area warrants continuous and rigorous monitoring. The SARS-CoV-2 spike protein 387 not only moderates viral infectivity and cellular uptake, but is also a target for vaccine and 388 monoclonal antibody therapeutic development. While vaccines are designed to elicit a 389 polyclonal immune response, the primary target of the vaccine response is currently a

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

16

monogenic antigen, and monoclonal antibody cocktails like those produced earlier this year run
the risk of selection for spike variants that escape those treatments (27).

392

393 In conclusion, a new protein coding spike variant, S:N679S, has been discovered in a clinically-394 unique patient in Washington, D.C. Analysis of global data shows that presence of the variant 395 was tolerated by SARS-CoV-2 in at least four different viral lineages, one of which shows 396 evidence of transmission of the variant to recipients in the US mid-Atlantic region. One of these 397 lineages presented within the CNH catchment area, showing viral sequence similarity to our 398 case. Variation in emerging infectious disease is expected, but this finding underscores the 399 need for larger-scale whole viral genome monitoring to ensure that responses can be quickly 400 adapted in the face of viral evolution. Until then, variants will continue to circulate undetected, 401 hindering the global response to SARS-CoV-2. Progress toward the defeat of the COVID-19 402 pandemic will require effective application of public health measures and wide-scale vaccination 403 alongside careful monitoring for emergence of viral escape variants.

404

#### 405 MATERIALS AND METHODS

406 Initial COVID-19 Screening. Initial COVID-19 screening was performed at CNH using either the Diasorin Liaison® MDX-Simplexa™ COVID-19 Direct real-time PCR assay or the Seegene 407 408 Allplex<sup>™</sup> 2019-nCoV real-time PCR assay. Both assays are gualitative and can be performed 409 using nasopharyngeal swab, oropharyngeal swabs, or saliva collections. The Diasorin Molecular 410 Simplexa COVID-19 assay allows for direct amplification of the ORF1ab region and the S gene 411 (Spike glycoprotein) present in the viral sample. The Seegene Allplex COVID-19 assay requires 412 viral RNA extraction prior to amplification and uses the Bio-Rad CFX96 real-time PCR 413 thermocycler for detection. This assay uses primers designed to detect the presence of the E

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

17

gene (an envelope protein), RdRP (RNA-dependent RNA polymerase), and the N gene (anucleoprotein).

416

RNA extraction and cDNA generation. Viral RNA was extracted with the Qiagen EZ1® DSP 417 418 Virus Kit, a magnetic bead-based kit. The concentration of the viral RNA was assessed using 419 the NanoDrop One. To perform Sanger confirmation on targeted variants, the viral RNA 420 underwent reverse transcriptase cDNA generation using the High Capacity cDNA Reverse 421 Transcription kit manufactured by Applied Biosystems. The RT master-mix was prepared 422 according to manufacturer recommendations excluding the 10X RT Random Primers, as we 423 had designed our own primers based on the sequencing data. To avoid potential primer bias, 424 cDNA was synthesized using three different initiation sites in the viral genome 425 426 Viral sequencing. Sequence data was generated on the Illumina MiSeg platform as a part of a 427 collaborative effort between CNH and Children's Hospital of Los Angeles with institutional 428 review board approval. Following previously described methodology (28), the CleanPlex SARS-429 CoV-2 NGS Panel kit (Paragon Genomics, Inc., Hayward, CA) was used to produce cDNA and 430 then amplify the SARS-CoV-2 genome in two multiplex PCR reactions containing 171 and 172 431 primer pairs each, producing amplicons ~150bp in length, and covering nearly the entire viral 432 genome once assembled (~100bp missing on each end). Assembly was performed using the 433 NovoAlign v4.02.00 algorithm with NC 045512 as the SARS-CoV-2 reference sequence. 434 435 Sanger confirmation. At completion of reverse transcription, Sanger sequencing of selected 436 variants identified by NGS was performed. We utilized the AccuPrime<sup>™</sup> Tag DNA Polymerase 437 System manufactured by Invitrogen™. A total of 10 PCR reactions containing different forward

438 and reverse primer pairings were prepared to confirm the observed variants. Thermocycler

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

18

- 439 conditions: denature 94°C 30s, anneal 55°C 30s, extend 68°C 60s, for 30 cycles. The final PCR
- 440 products were run on a 2% E-Gel to assess for presence of bands and fragment sizes. The
- 441 PCR products were Sanger sequenced by GeneWiz (Frederick, MD).
- 442
- 443 **RT primers:** 444 23902r\* TAAATTTGTTTGACTTGTGCAAAAACT 445 24527r CCTGTGATCAACCTATCAATTTGCACTTCAGC 446 24609r AAGATTAGCAGAAGCTCTGATTTCTG 447 448 PCR primers: 449 23320\_M13F\* CATTACACCATGTTCTTTTGGTGGTGT 450 23727\_M13R\*TAGACACTGGTAGAATTTCTGTGGTAA 451 23381 M13F CAGGTTGCTGTTCTTTATCAGGGT 452 23902\_M13R TAAATTTGTTTGACTTGTGCAAAAACT 453 23564\_M13F GCAGGTATATGCGCT 454 24038 M13R GCCAGCATCTGCAAGTGTCAC 455 23902 M13F TTTTGCACAAGTCAAACAAATTTA 456 24570\_M13R GTTGAGTCACATATGTCTGCAAAC 457 \*used to generate the representative chromatogram shown in **Fig 4**. Primer 458 sequences shown 5' to 3' for their respective strands. M13 sequencing tags have 459 been removed for clarity.
- 460

461 **Data access.** GISAID is presently the leader in viral sequence data sharing, having rapidly

462 expanded their influenza data sharing capabilities to suit the COVID-19 pandemic (29). All data

463 from samples outside of CNH were accessed from the GISAID database in accordance with

- their data sharing agreement (30). As of submission, sequences from CNH have not been
- 465 assigned GISAID accession IDs, but will be available in that repository.

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

19

466
-----

467	Phylogenetics. Consensus sequences were generated from variant calls with bcf tools on the
468	SARS-CoV-2 reference sequence from Wuhan, China (NC_045512) (31). MSA were generated
469	from consensus sequences from CNH samples and from GISAID through ClustalW alignment
470	on default settings (32). An ML phylogenetic tree was generated on the MSA with MEGA 7.0
471	(33, 34). All tree files were visualized with Interactive Tree of Life (35).
472	
473	Variant analysis. The NextClade and CoV-Glue tools were used for variant analysis (18, 36)
474	and compared to clade, lineage, and global distribution of related sequences via the PANGOLIN
475	(37) tool. NextClade assesses variation by aligning a query sequence to the SARS-CoV-2
476	reference sequence by scanning 21-mers across the genome followed by a banded Smith-
477	Waterman alignment with affine gap penalty, while CoV-GLUE leverages MAFFT (38) and
478	RAxML (39), with detailed methods described in their preprint. PANGOLIN leverages MAFFT
479	(38) and IQ-TREE 2 (40), with methods previously described. All relevant files are available as
480	<u>S3</u> .
481	
482	Proteinase cleavage site prediction. A multifasta of S1/S2 cleavage site was uploaded to
483	ProP1.0 for analysis and prediction of cleavage sites (41). Scores were exported and organized
484	by of GISAID variants. <u>S2</u> .
485	
486	Acknowledgements:
487	We acknowledge the critical efforts of Kristen Kocher, Melissa Andrew, and Miguel Almalvez
488	who made viral transport media and sample collection kits during the shortage which occurred
489	in spring and summer 2020.

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

20

491	We a	cknowledge Tara Workman, Hasani Malcolm, Farzana Siddiqui, Katy Draper, and Ashenafi
492	Melka	amu who ran SARS-CoV-2 PCR tests; Eric Freemen, William Suslovic, and Aszia Burrel
493	who d	coordinated the clinical research program; Michael Evangelista and Joyce Granados who
494	contri	buted from the microbiology department.
495		
496	We a	cknowledge the GISAID consortium for their comprehensive work. We acknowledge the
497	speci	fic originating labs: Maryland Public Health Laboratory, Virginia Division of Consolidated
498	Labo	ratory Services, Royal Hobart Hospital, Australia, Pathogen Genomics Center at the Japan
499	Natio	nal Institute of Infectious Disease, Labrotorio Central de Saude Publica do Estado do Rio
500	Gran	de do Sul, and Respiratory Viruses Branch, US CDC. ( <b><u>S4</u></b> )
501		
502	Our f	unders included the Ikaria Fund, and the A. James Clark Distinguished Professorship,
503	CNH	and the Saban Research Institute at CHLA intramural support for COVID-19 Directed
504	Rese	arch.
505		
506	REFE	RENCES
507	1.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
508		Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from
509		Patients with Pneumonia in China, 2019. N Engl J Med 382:727–733.
510	2.	Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, Queen K, Tao Y, Paden C,
511		Zhang J, Li Y, Uehara A, Wang H, Goldsmith C, Bullock H, Wang L, Whitaker B, Lynch B,
512		Gautam R, Schindewolf C, Lokugamage K, Scharton D, Plante J, Mirchandani D, Widen
513		S, Narayanan K, Makino S, Ksiazek T, Plante K, Weaver S, Lindstrom S, Tong S,
514		Menachery V, Thornburg N. 2020. Isolation and characterization of SARS-CoV-2 from the
515		first US COVID-19 patient. bioRxiv Prepr Serv Biol 2020.03.02.972935.

516 3. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, Cui J, Lu

J. 2020. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 7:1012-

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

517

- 518 1023. 519 Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T. 2020. Coronavirus 4. 520 Disease 2019 in Children — United States, February 12–April 2, 2020. MMWR Morb 521 Mortal Wkly Rep 69:422–426. 522 5. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò 523 Carducci FI, Gabrovska N, Velizarova S, Prunk P, Osterman V, Krivec U, Lo Vecchio A, 524 Shingadia D, Soriano-Arandes A, Melendo S, Lanari M, Pierantoni L, Wagner N, L'Huillier 525 AG, Heininger U, Ritz N, Bandi S, Krajcar N, Roglić S, Santos M, Christiaens C, Creuven 526 M, Buonsenso D, Welch SB, Bogyi M, Brinkmann F, Tebruegge M, Pfefferle J, 527 Zacharasiewicz A, Berger A, Berger R, Strenger V, Kohlfürst DS, Zschocke A, Bernar B, 528 Simma B, Haberlandt E, Thir C, Biebl A, Vanden Driessche K, Boiy T, Van Brusselen D, 529 Bael A, Debulpaep S, Schelstraete P, Pavic I, Nygaard U, Glenthoej JP, Heilmann 530 Jensen L, Lind I, Tistsenko M, Uustalu Ü, Buchtala L, Thee S, Kobbe R, Rau C, Schwerk N, Barker M, Tsolia M, Eleftheriou I, Gavin P, Kozdoba O, Zsigmond B, Valentini P, 531 532 Ivaškeviciene I. Ivaškevicius R. Vilc V. Schölvinck E. Rojahn A. Smvrnajos A. Klingenberg C, Carvalho I, Ribeiro A, Starshinova A, Solovic I, Falcón L, Neth O, Minguell 533 534 L, Bustillo M, Gutiérrez-Sánchez AM, Guarch Ibáñez B, Ripoll F, Soto B, Kötz K, 535 Zimmermann P, Schmid H, Zucol F, Niederer A, Buettcher M, Cetin BS, Bilogortseva O, Chechenyeva V, Demirjian A, Shackley F, McFetridge L, Speirs L, Doherty C, Jones L, 536 537 McMaster P, Murray C, Child F, Beuvink Y, Makwana N, Whittaker E, Williams A, Fidler
- 538 K, Bernatoniene J, Song R, Oliver Z, Riordan A. 2020. COVID-19 in children and
- adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc
  Heal 4:653–661.
- 541 6. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, Ansusinha E, Hahn A,
- 542 Hamdy R, Harik N, Hanisch B, Jantausch B, Koay A, Steinhorn R, Newman K, Wessel D.

- 543 2020. Severe Coronavirus Disease-2019 in Children and Young Adults in the
- 544 Washington, DC, Metropolitan Region. J Pediatr 223:199-203.e1.
- 545 7. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger
- 546 JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi P,
- 547 Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA,
- 548 Alharash H, Doymaz S, Clouser KN, Giuliano JS, Gupta A, Parker RM, Maddux AB,
- 549 Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL,
- 550 Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hobbs C V., Marohn KL,
- 551 Halasa NB, Patel MM, Randolph AG. 2020. Multisystem Inflammatory Syndrome in U.S.
- 552 Children and Adolescents. N Engl J Med 383:334–346.
- 553 8. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, Roguski K, Wallace
- 554 B, Prezzato E, Koumans EH, Lee EH, Geevarughese A, Lash MK, Reilly KH, Pulver WP,
- 555 Thomas D, Feder KA, Hsu KK, Plipat N, Richardson G, Reid H, Lim S, Schmitz A, Pierce
- 556 T, Hrapcak S, Datta D, Morris SB, Clarke K, Belay E. 2020. COVID-19–Associated
- 557 Multisystem Inflammatory Syndrome in Children United States, March–July 2020.
- 558 MMWR Morb Mortal Wkly Rep 69:1074–1080.
- 559 9. COVID-19 Surveillance. Washington, DC Gov. https://coronavirus.dc.gov/data
- 560 10. The White House. 2020. Suspension of Entry as Immigrants and Nonimmigrants of
- 561 Certain Additional Persons Who Pose a Risk of Transmitting 2019 Novel Coronavirus.
- 562 Fed Regist. https://www.federalregister.gov/documents/2020/02/05/2020-
- 563 02424/suspension-of-entry-as-immigrants-and-nonimmigrants-of-persons-who-pose-a 564 risk-of-transmitting-2019
- 565 11. The White House. 2020. Suspension of Entry as Immigrants and Nonimmigrants of
- 566 Persons Who Pose a Risk of Transmitting 2019 Novel Coronavirus and Other
- 567 Appropriate Measures To Address This Risk. Fed
- 568 Regist. https://www.federalregister.gov/documents/2020/03/16/2020-05578/suspension-

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

- 569 of-entry-as-immigrants-and-nonimmigrants-of-certain-additional-persons-who-pose-a-
- 570 risk-of
- 12. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou
- 572 J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B,
- 573 Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY. 2020. Spike
- 574 mutation D614G alters SARS-CoV-2 fitness. Nature 1–6.
- 575 13. Duckert P, Brunak S, Blom N. 2004. Prediction of proprotein convertase cleavage sites.
  576 Protein Eng Des Sel 17:107–112.
- 577 14. Bertram S, Glowacka I, Muller MA, Lavender H, Gnirss K, Nehlmeier I, Niemeyer D, He
- 578Y, Simmons G, Drosten C, Soilleux EJ, Jahn O, Steffen I, Pohlmann S. 2011. Cleavage579and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by

580 Human Airway Trypsin-Like Protease. J Virol 85:13363–13372.

- 581 15. Xia S, Lan Q, Su S, Wang X, Xu W, Liu Z, Zhu Y, Wang Q, Lu L, Jiang S. 2020. The role
- 582 of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the

583 presence or absence of trypsin. Signal Transduct Target Ther. Springer Nature.

16. Klimstra W, Tilston-Lunel N, Nambulli S, Boslett J, McMillen C, Gilliland T, Dunn M, Sun

- 585 C, Wheeler S, Wells A, Hartman A, McElroy A, Reed D, Rennick L, Duprex WP. 2020.
- 586 SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from
- 587 acutely infected, hospitalized COVID-19 patients. bioRxiv Prepr Serv Biol
- 588 https://doi.org/10.1101/2020.06.19.154930.
- 589 17. Nguyen HT, Zhang S, Wang Q, Anang S, Wang J, Ding H, Kappes JC, Sodroski J,
- 590 Sodroski JG. 2020. Spike glycoprotein and host cell determinants of SARS-CoV-2 entry
- and cytopathic effects Downloaded from https://doi.org/10.1128/JVI.02304-20.
- 18. Hodcroft E, Aksamentov I, Stroud N, Neher R, Sibley T. 2020. Nextclade.
- 593 19. Excess Deaths Associated with COVID-19. US
- 594 CDC. https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess\_deaths.htm

- 595 20. 2021. COVID-19 Map. Johns Hopkins Coronavirus Resour Cent.
- 596 21. Kirby T. 2021. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet
- 597 Respir Med https://doi.org/10.1016/S2213-2600(21)00005-9.
- 598 22. 2020. SARS-CoV-2 Variant United Kingdom of Great Britain and Northern Ireland.
- 599 WHO. World Health Organization. http://www.who.int/csr/don/21-december-2020-sars-
- 600 cov2-variant-united-kingdom/en/
- 601 23. Ventola CL. 2015. The antibiotic resistance crisis: causes and threats. P T J 40:277–83.
- 602 24. Windels EM, Michiels JE, van den Bergh B, Fauvart M, Michiels J. 2019. Antibiotics:
- 603 Combatting tolerance to stop resistance. MBio 10.
- 604 25. Emerging SARS-CoV-2 Variants. US CDC.
- 605 26. Cohen E. 2021. CDC hopes to check more samples for new Covid strain. CNN.
- 606 27. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment
- 607 of COVID-19. US FDA. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-
- 608 research/scientific-brief-emerging-variants.html
- 28. Pandey U, Yee R, Shen L, Judkins AR, Bootwalla M, Ryutov A, Maglinte DT, Ostrow D,
- 610 Precit M, Biegel JA, Bender JM, Gai X, Bard JD. 2020. High Prevalence of SARS-CoV-2
- 611 Genetic Variation and D614G Mutation in Pediatric Patients with COVID-19. Open Forum 612 Infect Dis https://doi.org/10.1093/ofid/ofaa551.
- 613 29. LoTempio J, Spencer D, Yarvitz R, Delot-Vilan A, Vilain E, Delot E. 2020. We Can Do
- 614 Better: Lessons Learned on Data Sharing in COVID-19 Pandemic Can Inform Future
- 615 Outbreak Preparedness and Response. Sci Dipl.
- 616 30. GISAID Data Access Terms of Use. GISAID
- 617 Consort. https://www.gisaid.org/registration/terms-of-use/
- 618 31. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwham A, Keane
- 619 T, McCarthy SA, Davies RM, Li H. 2020. Twelve years of SAMtools and BCFtools.
- 620 32. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: Improving the sensitivity of

- 621 progressive multiple sequence alignment through sequence weighting, position-specific
- 622 gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680.
- 623 33. Hall BG. 2013. Building Phylogenetic Trees from Molecular Data with MEGA. Mol Biol
- 624 Evol 30:1229–1235.
- 625 34. Kumar S, Stecher G, Tamura K. 2016. MEGA7: Molecular Evolutionary Genetics Analysis
- 626 Version 7.0 for Bigger Datasets. Mol Biol Evol 33:1870–1874.
- 627 35. Letunic I, Bork P. 2019. Interactive Tree of Life (iTOL) v4: Recent updates and new
  628 developments. Nucleic Acids Res 47:W256–W259.
- 629 36. Singer JB, Gifford RJ, Cotten M, Robertson DL. 2020. CoV-GLUE: A Web Application for
- 630 Tracking SARS-CoV-2 Genomic Variation
- 631 https://doi.org/10.20944/preprints202006.0225.v1.
- 632 37. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG.
- 633 2020. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
- 634 epidemiology. Nat Microbiol 5:1403–1407.
- 635 38. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7:
- 636 Improvements in performance and usability. Mol Biol Evol 30:772–780.
- 637 39. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis
  638 of large phylogenies. Bioinformatics 30:1312–1313.
- 40. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A,
- 640 Lanfear R. 2020. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
- 641 Inference in the Genomic Era. Mol Biol Evol 37:1530–1534.
- 642 41. Duckert P, Brunak S, Blom N. 2004. Prediction of proprotein convertase cleavage sites.
  643 Protein Eng Des Sel 17:107–112.
- 644
- 645
- 646


- 647 FIGURES

- ....


- \_ \_ \_ \_

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

673	
674	
675	
676	
677	
678	
679	
680	
681	
682	Fig 1. A) Maximum-likelihood phylogenetic tree of 27 SARS-CoV-2 positive patients. This
683	tree was constructed from a ClustalW multiple sequence alignment and visualized with the
684	Interactive Tree of Life GUI. Solid branches represent divergence in substitutions per
685	nucleotide, while dashed lines are added for ease of interpretation. Colors represent the GISAID
686	clade to which each sample belongs. B) Time series plot of the GISAID clades of GISAID
687	submissions over time in select cities. Sequence metadata were accessed from GISAID to
688	establish coarse differences in viral population diversity over time.
689	
690	
691	
692	
693	
694	
695	
696	
697	
698	




∎GH ∎GR ∎G ∎S ■V




Novel SARS-CoV-2 spike variant identified in Washington, D.C.

700	
701	
702	
703	
704	
705	
706	
707	
708	
709	
710	
711	Fig 2. Global network of SARS-CoV-2. Representation of the locations where the highest
712	number of sequences assigned to a given PANGOLIN lineage can be found in relation to DC
713	sequences
714	
715	
716	
717	
718	
719	
720	
721	
722	
723	
724	

Novel SARS-CoV-2 spike variant identified in Washington, D.C.






3

726	
727	
728	
729	
730	
731	
732	
733	
734	
735	
736	Fig 3. Clustering of detected SARS-CoV-2 viral genome variants with disease outcome.
737	Bi-clustering of the binary variant matrix of SARS reveals a diverse cluster of variants and five
738	patients with identical viral genomic profiles. The condition of each patient is depicted indicated
739	primary COVID-19 (blue) and MIS-C (red). Variants identified across the cohort were
740	aggregated and a binary matrix was generated for each patient and variant. Red colored boxes
741	indicate the detection of a variant within that case.
742	
743	
744	
745	
746	
747	
748	
749	
750	


4

Novel SARS-CoV-2 spike variant identified in Washington, D.C.



Novel SARS-CoV-2 spike variant identified in Washington, D.C.

752	
753	
754	
755	
756	
757	
758	
759	
760	Fig 4. A-E) Histograms of viral PCR test cycle threshold values. Vertical red line indicates
761	the detected RT-PCR of the S:N679S case. A) Diasorin ORF Ct distribution B) Diasorin S gene
762	Ct distribution. C) Seegene RT-PCR E gene Ct distribution. D) Seegeen R gene Ct distribution.
763	E) Seegene N gene Ct distribution. F) Short-read pileup at the coding region for spike protein
764	variant of interest, S:N679S. The read pileup shows strong homozygous signal (>9,000x
765	coverage) for a non-synonymous variant in the viral spike protein. <b>G)</b> Sanger sequence
766	confirmation of variant of interest, S:N679S. Chromatogram showing a contiguous span
767	containing the previously characterized D614G variant and linkage to the S:N679S variant of
768	interest.
769	
770	
771	
772	
773	
774	
775	
776	





Novel SARS-CoV-2 spike variant identified in Washington, D.C.

778	
779	
780	
781	
782	
783	
784	
785	
786	
787	Fig 5 A) Maximum likelihood phylogenetic tree of all high-quality sequences in GISAID
788	with variant S:N679S in the spike protein. A non-reference sample from Wuhan collected in
789	December 2019 was used as the outgroup in this tree to draw contrast between clades. Clade
790	G in yellow shows the high-quality sequences in lineage B.1.189 where spike variant S:N679S
791	has emerged. Clade GR in yellow shows three separate evolutionary events resulting in spike
792	variant S:N679S. B) Time series plot of the count, by location, of sequences in GISAID
793	belonging to PANGOLIN lineage B.1.189. Sequence metadata were accessed from GISAID
794	to establish coarse differences in viral population diversity over time.

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

April

March

May

June

July


August

September

October

November

Texas
 California





9

Novel SARS-CoV-2 spike variant identified in Washington, D.C.

## 796 SUPPLEMENT LEGEND

- 797
- 798 S1: List of case IDs, clades, and disease status
- 799 S1\_Case\_clade\_and\_disease\_status\_12\_21\_2020.csv
- 800 S2\_A: ProP scores
- 801 S2\_A\_GISAID\_Spike\_residue\_679\_variant\_scores\_15\_jan\_2021.pdf
- 802 S2\_B: Amino acid substitution multifasta
- 803 S2\_B\_679\_aa\_sub.fa
- 804 S3\_A: Coding and non-coding variants in sequences with S:N679S
- 805 S3\_A\_B1189\_N679S\_variant\_summary.pdf

## 806 S3\_B: Variants called via NextClade

- 807 S3\_B\_NextClade\_variants.xlsx
- 808 S4: Acknowledgements from originating labs, GISAID
- 809 S4\_gisaid\_hcov-19\_acknowledgement\_table\_high\_quality\_spike\_n679S.pdf